FibroGen, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
FGEN Nasdaq 2834 www.fibrogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for FibroGen, Inc.

FibroGen Appoints David DeLucia as Chief Financial Officer - Dec 16th, 2024 1:05 pm
FibroGen Third Quarter 2024 Earnings: Beats Expectations - Nov 15th, 2024 10:04 am
Q3 2024 FibroGen Inc Earnings Call - Nov 13th, 2024 3:22 pm
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions - Nov 13th, 2024 7:21 am
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - Nov 12th, 2024 11:10 pm
FibroGen: Q3 Earnings Snapshot - Nov 12th, 2024 10:06 pm
FibroGen Reports Third Quarter 2024 Financial Results - Nov 12th, 2024 9:05 pm
FibroGen to Report Third Quarter 2024 Financial Results - Nov 4th, 2024 9:05 pm
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts - Oct 9th, 2024 9:09 pm
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 8:05 pm
FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Aug 9th, 2024 10:39 am
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates - Aug 6th, 2024 10:15 pm
FibroGen: Q2 Earnings Snapshot - Aug 6th, 2024 9:10 pm
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update - Aug 6th, 2024 8:05 pm
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials - Jul 31st, 2024 3:54 pm
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone - Jul 31st, 2024 11:33 am
FibroGen to Report Second Quarter 2024 Financial Results - Jul 30th, 2024 8:07 pm
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update - Jul 30th, 2024 8:05 pm
FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54% - Jul 29th, 2024 11:41 am
Favourable Signals For FibroGen: Numerous Insiders Acquired Stock - Jun 18th, 2024 1:02 pm